Abdi Ibrahim Pharmaceuticals (PRIVATE.ABDIIBRAHIM)

Overall impact
B (70)

Commentary

Abdi Ibrahim Pharmaceuticals is a strong overall performer. With a 'B' rating of 70.2 for overall impact (82nd percentile compared to all companies), Abdi Ibrahim Pharmaceuticals ranks 55th out of 154 industry peers, behind Adamis Pharmaceuticals, Benitec Biopharma, Aquinox Pharmaceuticals and 51 others, and ahead of Evolus, DiaMedica Therapeutics, Centrexion Therapeutics and 96 others. On top material causes for Abdi Ibrahim Pharmaceuticals's industry (Pharmaceuticals & Biotech), Abdi Ibrahim Pharmaceuticals performs well in Disease Eradication (96.3 score), Child and Maternal Health (92.0) and Improved Mental Health (81.9). Abdi Ibrahim Pharmaceuticals did not receive a 'D' or 'F' rating on any cause.
Impact
Cause PRIVATE.ABDIIBRAHIM
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2012
Employees
79
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Turkey
Share classes
PRIVATE.ABDIIBRAHIM
More info
Description
Operator of a pharmaceutical company focused on offering innovative pharmaceuticals in various treatment fields in order to serve the well-being of Turkey. The company provides medicine and treatment for schizophrenia, autism bipolar disorder, depression, hyponatremia, polycystic kidney disease, resistant tuberculosis, intermittent kladikasyo, bone marrow transplantation.
Material causes
Ethos considers the following causes material for Abdi Ibrahim Pharmaceuticals, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.